Abstract
Introduction:
The coexistence of diabetes mellitus (DM) and hypertension (HT) is very common; both pathologies seem to share different mechanisms such as insulin resistance (IR), endothelial dysfunction, increase in reactive oxygen species (ROS), among others. Furthermore, exposure to hyperglycemia during gestational development has been defined as a risk factor for cardiovascular disease (CVD) in adulthood. However, the mechanisms involved in this “prenatal programming” are still unclear. This review aims to identify the mechanisms involved in the relationship between DM and HT, both in their coexistence and in the development of HT in offspring derived from gestational diabetes (GD). There are no reviews that comprehensively cover both the link between HT and DM as well as the risk factors in mothers with GD and the cardiovascular effects in their offspring.
Methods:
A search of published studies reporting HT in offspring of diabetic pregnancies, either in animals or humans, prevalence and pathophysiological mechanisms of binomial hypertension-diabetes (HT/DM), mechanisms, metabolic alterations, DM and HT in pregnancy was done. Inclusion criteria were studies investigating the cardiovascular effects of GD on offspring, studies in animal models or humans, reviews and meta-analyses.
Results:
87 studies were included. IR is the main common factor between the presence of DM and the development of HT, in addition to inflammatory processes. Maternal pathology before pregnancy favors the development of diabetes and HT during pregnancy. Animal studies have shown that 100% of the offspring of mothers with GD have HT, mostly after 12 weeks of age. In human studies, there is a significant difference in the blood pressure (BP) levels of the offspring of mothers with gestational hyperglycemia compared with control mothers from the age of 2 years. Several mechanisms such as structural changes in the arterial wall, endoplasmic reticulum (RE) stress, increase in ROS and decrease in nitric oxide (NO) synthesis are proposed as some of the possible culprits.
Conclusion:
Current evidence shows that the interaction between DM and HT occurs through mechanisms that they share in their pathogenesis, that is, the presence of one lead to the other and the hyperglycemia to which infants are exposed in utero makes them more susceptible to CVD.
Introduction
DM and HT are two components that coexist worldwide, increasing the risk of CVD and renal disease, as well as the mortality of those who suffer from them. The importance of knowing the bidirectional relationship that exists between both makes it possible to acquire tools for prevention and adequate management of its complications ().
One of the non-modifiable risk factors that implies that these pathologies are present in a large proportion in the world population is genetic load. Mothers who develop it, either before pregnancy or during it, predispose their offspring to the imminent risk of chronic diseases in adulthood.
In this review, we analyze the coexistence of HT and DM, their prevalence, mechanisms involved, risk factors and associated complications specifically in women during pregnancy, and the development of hypertension in offspring, as well as to review the animal models proposed to recreate these conditions and to evaluate the physiological changes proposed as possible responsible.
Our work arises from the lack of reviews that provide an overview of the undeniable link between HT and DM as well as the risk of suffering from these diseases during pregnancy and the adverse effects on their offspring.
The objective of this review is to give a general overview of two highly relevant topics that involve the health of the pregnant mother and her offspring.
Methodology
Literature search
Systematic search of published studies reporting HT and DM. All types of publications, original articles, cohort studies, meta-analyses and reviews were considered. The search was conducted in PubMed (www.ncbi.nlm.nih.gov) and Web of Science (www.webofscience.com) for studies published before February 2025 using Medline subject heading (MeSH) keywords: [Diabetes Mellitus] [Hypertension] [Hypertension AND Diabetes Mellitus] [Prevalence of Hypertension-Diabetes] [pathophysiological mechanisms hypertension-diabetes] [Gestational diabetes AND hypertension in offspring] also, the filter of free full text was applied. The review included animal and human studies. The search was conducted independently by AMH and GEDL from June 2024 to February 2025. Relevant studies were identified from the abstract and selected articles were assessed in full text to determine which would be useful in preparing the review. The data obtained from each article were those that provided valuable information according to the inclusion criteria. Both observational articles were considered, but in the case of animal models it was important that interventions were carried out. For data synthesis, individual summaries and a table were made to synthesize the animal models used to induce GD. (Figure 1).
FIGURE 1
Inclusion and exclusion criteria
The inclusion criteria were studies that explored the relationship between HT and DM, their current prevalence, shared pathophysiological mechanisms, the cardiovascular (CV) effects of GD in offspring, studies in animal or human models, reviews and meta-analysis articles. The exclusion criteria were articles without full text, pilot studies, studies with incomplete or insufficient data.
Data classification
The classification of the selected studies was carried out in four categories: original articles in animals, original articles in humans, reviews and articles that proposed shared mechanisms in pathophysiology, worldwide statistics, associated risk factors in women of reproductive age and pregnant women, signaling pathways involved in the development of HTN/DM and CV pathology of the offspring.
Data extraction
The following data were extracted from each of the included studies: metabolic pathways, risk factors, epidemiology and prevalence. Study characteristics: first author, published year, study setting, and study design; glucose levels in the mothers, BP measurement and other vascular outcomes of offspring and possible mechanisms proposed for these pathologies.
Presence of diabetes and hypertension in the world population
According to the World Health Organization (WHO) in 2021, an estimated 537 million adults (ages 20–79) were living with diabetes. The number of people with diabetes is expected to increase to 643 million in 2030 and 783 million in 2045. DM is a leading cause of CVD and mortality (World Health Organizationa).
The WHO estimates that there are 1.28 billion adults aged 30–79 years with HT worldwide and it constitutes the main CV risk factor and is one of the main causes of premature death worldwide; Its prevalence continues to increase (). Various factors increase the risk of developing HT and include genetic causes, advanced age, alcoholism, overweight or obesity, smoking, unhealthy diets and a sedentary lifestyle (; ).
Over time, we have seen that CVD is the leading cause of morbidity and mortality in diabetic patients (). HT occurs in more than 50% of patients with DM; on the other hand, diabetic patients with HT are four times more likely to develop CVD (). Thus, we have two relationships, one suggesting that DM increases the risk of HT, and another showing the relationship between the initial presence of HT and the subsequent occurrence of DM (; ).
Coexistence between diabetes and hypertension
It is important to mention that the close relationship between DM and HT is also the result of the fact that patients with diagnosed and treated DM maintain stricter BP monitoring than the rest of the population, which favors detection and early initiation of antihypertensive therapy (). In addition, the use of some antihypertensive medications, such as the combination of high-dose thiazides and β-blockers, is associated with an increased risk of DM. Some hypoglycemic medications can induce sodium and fluid retention, which can lead to an increase in BP (; ).
Many previous studies have shown that HT and DM share common risk factors, including age, gender, smoking, sedentary lifestyle, family history, poor dietary habits, high body mass index (BMI), and waist circumference. Obesity in terms of BMI is the main cause of these diseases (). They also share pathophysiological pathways that are interrelated and may even lead to a vicious cycle, which we will focus on later ().
It is still unclear whether the increased risk resulting from the coexistence of DM, and HT is due to a simple combination or to their interactions; nevertheless, their coexistence is no coincidence (). Some studies have suggested that this bidirectional relationship has a genetic component, with genetic DM being the one that increases the risk of HT. They even suggest the presence of accelerated arterial stiffness resulting from DM, which is associated with a greater increase. of heart rate (HR) and BP specifically systolic (SBP).
Pathophysiological mechanisms shared
This binomial shares several pathogenic pathways such as obesity, IR, pancreatic β-cell dysfunction, inflammation, oxidative stress, vascular dysfunction, sodium retention, sympathetic excitation, activation of the renin-angiotensin-aldosterone system (RAAS), and renal damage (Figure 2) ().
FIGURE 2
Evidence suggests that the association between obesity and DM in hypertensive patients, as well as IR in obesity and HT, share not one but several pathophysiological factors (). One is the presence of higher HR, which is an important marker of CV risk in DM, something we also observe in obesity (); this is a measure of sympathovagal balance (). HR may be an indicator of impaired sympathetic nervous system (SNS) function associated with DM; although HR alone does not necessarily confer risk of HT, it is the sympathovagal imbalance that causes diabetic patients to develop HT ().
The combination of both chronic diseases has adverse effects on left ventricular structure, myocardial dysfunction, and arterial stiffness. Both DM and HT are risk factors for the development of atherosclerosis and are essential components of the deterioration and exacerbation of endothelial and smooth muscle function. Their combination promotes endothelial cell dysfunction by generating oxygen-derived free radicals that damage endothelial function. They also promote monocyte adhesion to endothelial cells, thereby increasing vascular superoxide production and monocyte chemoattractant protein-1 expression, leading to atherosclerosis and subsequent cerebrovascular/CV disease ().
A widely recognized mechanism is inflammation, which is the main pathological process in many diseases (). Low-grade inflammation induced by IR is the main mechanism explaining the development of endothelial dysfunction and metabolic abnormalities in obesity ().
In inflammatory metabolic disorders proinflammatory cytokines (tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and monocyte chemoattractant protein-1) can alter insulin metabolic signaling and reduce insulin-mediated nitric oxide (NO) production, leading to arterial stiffness and HT. Furthermore, systemic and tissue inflammation are strongly related to abdominal obesity (); since macrophage infiltration is an important driver of adipose tissue inflammation and metabolic disorders associated with HT. In the setting of obesity, IR, and DM, adipokines from perivascular adipose tissue contribute to vascular IR and impaired relaxation ().
The current literature strongly supports the idea that HT and DM share another common pathophysiological mechanism: IR; this is defined as a biological effect that is lower than expected in response to a given concentration of the hormone and this plays a fundamental role in the pathogenesis of DM (). In untreated fasting hypertensive patients, postprandial insulin levels are higher than in normotensive patients; similarly, it has been documented that rats with genetic HT such as DAHL or SHR strains show IR and hyperinsulinemia (). And in rats fed for 6 months with a high-calorie diet, they show that the increase in BP and the development of left ventricular hypertrophy are associated with hyperinsulinemia or hyperglycemia ().
It is important to note that insulin is a hormone that does not exclusively affect glucose metabolism, but also affects lipid and protein metabolism, ion and amino acid transport, cell cycle, proliferation and differentiation, and NO synthesis ().
IR also contributes to elevated BP through other mechanisms, including increased angiotensin II (AngII) and aldosterone activity (; ), and increased SNS activity (); in this sense in hypertensive patients, the SNS response to insulin has increased (). This increase in SNS tone impairs the vasorelaxant effect of insulin and contributes to elevated BP (). It also induces stimulation of β-adrenergic receptors that promote IR ().
Likewise, RAAS deregulation plays a fundamental role in the development of IR and HT; thus, prevention of DM in patients with HT requires therapeutic inhibition of the RAAS with angiotensin type 1 receptor (AT-1R) antagonists or angiotensin-converting enzyme (ACE) inhibitors (; ; ). In vivo and in vitro studies have shown that IR and hyperglycemia induce systemic activation of the RAAS associated with increased vascular resistance and BP. Ang II and aldosterone decreased activation of endothelial nitric oxide synthase (eNOS) and reduced NO-mediated vasodilation (). Hyperinsulinemia associated with insulin resistance stimulates production of the vasoconstrictor endothelin-1 (ET-1) contributes to excessive arterial stiffness, and HT. Hyperinsulinemia and aldosterone have been found to increase endothelial sodium channel activity, leading to arterial stiffness and HT (; ).
The existence of a common genetic pathway for HT and IR is supported by the altered glucose metabolism found in normotensive offspring of hypertensive patients (). In addition, specific genetic abnormalities have been identified in individuals with combinations of IR, obesity, dyslipidemia, and HT, such as mutations in β3-adrenergic receptors () or deficiency of CD36, a known fatty acid transporter involved in predisposition to IR and HT (). The relationship between IR and HT is a complex and multifactorial phenomenon involving both genetic and environmental factors, hence the importance of studying both those who suffer from it and their offspring.
How can the health of a pregnant women can be affected by diabetes and hypertension?
Of particular interest is the Women’s Health Study (), which showed that in healthy middle-aged women, progressive elevation of BP is a strong and independent predictor of DM. Similarly, the Monitoring Trends and Determinants on CVD/Cooperative Health Research study from the Augsburg region () showed that established HT in women significantly increase the risk of DM, and glucose intolerance and DM have a higher incidence of HT than men ().
Hypertensive disorders of pregnancy are common, affecting approximately 5%–9% of normal pregnancies. Given the increasing prevalence of HT, obesity, and DM in women of childbearing age and the societal trend toward advanced maternal age, published rates may underestimate recent incidence. These disorders are a major cause of maternal and neonatal morbidity and mortality. The diagnosis and management of HT in pregnancy requires attention to the maternal and fetal effects of the disease and its treatment ().
Hemodynamically, there are significant physiological changes in pregnancy and a reduction in systemic vascular resistance, RAAS is activated early in pregnancy without affecting BP. A decrease in BP influenced by the vasodilator relaxin, ovarian hormone, NO signaling and the vasodilatory state (; ).
Controlled chronic HT is usually well tolerated during pregnancy with minimal maternal and fetal complications; however, women with uncontrolled BP are at increased risk for poor obstetric outcomes and target organ damage. Gestational HT, or pre-eclampsia (PE), is the development of newly elevated BP after 20 weeks of gestation without evidence of maternal organ dysfunction; this should usually be resolved by 12 weeks postpartum (; ).
Gestational diabetes (GD) and PE are common complications of pregnancy with similar risk factors, including obesity, advanced age, and multiple gestation. In the United States (US), GD was diagnosed in 7.8 per 100 births, an increase of 30% since 2016. The Pan-American Health Organization reports that GD is diagnosed in one–two of every 10 pregnancies in the Americas, but cases continue to increase [49 50].
GD is defined as a blood glucose level higher than normal but lower than that which justifies a diagnosis of diabetes that appears during pregnancy (WHO) (Diabetes; ). In pregnant women there are three tests to establish the diagnosis of GD: casual blood glucose greater than 200 mg/dL and classic symptoms of diabetes; fasting glucose greater than 126 mg/dL on two or more occasions; and serum or plasma glucose concentration 1 hour after ingesting 50 g of glucose greater than 140 mg/dL (corroborated with an oral glucose tolerance curve with values greater than 180 mg/dL) (). Increased insulin resistance, pancreatic β-cell dysfunction are the main pathogenesis of GD, which may be present before pregnancy, especially in populations of women with obesity ().
Studies have shown that the incidence of PE increases significantly in the presence of GD. PE alone is the leading cause of maternal morbidity and fetal morbidity/mortality. However, GD complicated by PE further increases perinatal adverse events as well as the future risk of CVD and metabolic syndrome (MetS) in both the mother and offspring (for example, offspring BMI increases steadily over time); therefore, identifying factors associated with the occurrence of PE in women with GD, especially those that are controllable, is important to improve pregnancy outcomes (; ).
Furthermore, the pathophysiological processes in both GD and PE include oxidative stress, release of pro-inflammatory factors, and vascular endothelial dysfunction, which increase the risk of future maternal diabetes and CVD, as well as neonatal complications (; ).
The mechanisms of the association between GD and PE are not entirely clear. The pathophysiological process of PE involves placental ischemia, oxidative stress, increased levels of antiangiogenic factors in placenta that cause inflammation and vascular endothelial dysfunction (). On the other hand, GD can induce trophoblast inflammation, increase oxidative stress through a variety of pathways, including the formation of advanced glycation end products (AGEs), increased production of reactive oxygen species resulting in a decrease in NO levels which may promote the occurrence of PE. In addition, an increase in proinflammatory cytokines associated with endothelial dysfunction and PE has been observed in women with GD. Even TNF-α, IL-6 and C-reactive protein (CRP) have been suggested as independent risk factors for PE in women with GD ().
Another important factor influencing the development of PE in women with GD is obesity, which is one of the world’s major health problems. According to global estimates, the incidence of obesity has doubled in the last 4 decades and more than 30% of women are obese (). This epidemic increase in obesity is also reflected in a higher prevalence of maternal obesity. In the US, more than 50% of pregnant women are considered obese, while in Europe, the number of women considered overweight and obese during pregnancy has also increased significantly, reaching rates of 30%–37% (). Obesity has been shown to affect maternal and infant health by increasing the risk of adverse perinatal outcomes (; ).
Effects of gestational diabetes and hypertension on offspring
In the literature, we found that the coexistence of hypertension and gestational diabetes (GD) in mothers may disappear after birth, in offspring, it can cause complications throughout their lives and was associated with adverse neonatal outcomes, including small for gestational age at delivery and/or small for gestational age at birth, perinatal mortality, fetal macrosomia, malformations, congenital disease, respiratory distress syndrome, low APGAR, neonatal hypoglycemia and, in general, a higher incidence of offspring with metabolic disease in adulthood (). In turn, in the long term, a higher prevalence of obesity, insulin resistance, glucose intolerance, and vascular complications has been observed compared to offspring of mothers with normal blood glucose levels (Gob.mx; ).
The predisposition that descendants of mothers with GD have to suffer from CVD in adulthood, mainly HT, is gathering more evidence every day, presenting higher pressure values from the age of 3 years, this difference becoming increasingly greater with the passing of the time in their life concerning the offspring of mothers with normal blood glucose levels (; ; ; ) However, the mechanism by which this “metabolic programming” occurs is still not fully understood.
Animal models
The use of animal models has allowed us to further study the mechanisms involved in certain pathologies. In this case, the GD model has been generated in rats to then evaluate the CV effects in their offspring. The model used in general to develop diabetes in mothers is by intraperitoneally injecting streptozotocin (STZ), a drug that destroys the beta cells of the pancreas, so the rats stop producing insulin and this leads them to have high glucose levels. The values achieved range from 15 to 20 mM, that is, between 250 and 350 mg/dL. The STZ injection is done on day 0 of pregnancy, which is when the sperm plug is observed. High glucose concentrations are reached approximately after 3 days but are monitored throughout the pregnancy to corroborate the maintenance of hyperglycemia. Once the offspring are born, they remain with their mothers until weaning and that is when the evaluation of the BP values and any other parameters can begin. As shown in Figure 3 the device used to measure glucose levels in rats is the same one used in humans, but the one used to measure BP is one designed specifically for rodents. Three articles of the five selected in this review explain the animal model, refer to the onset of HT in the offspring of diabetic dams at 12 weeks of age (; ; ) while another two refer that these values were reached after 6 and 18 months respectively (; ). To perform molecular and/or tissue-specific tests on the offspring of diabetic mothers and control mothers, they are allowed to continue growing until a certain age and then the sacrifice is carried out.
FIGURE 3
Different proposed mechanisms could be involved in this development of HT in the children of mothers with GD. Lou et al., in two independent publications, report having observed an increase in ROS and ER stress; a decrease in the synthesis of NO; impaired diuresis and natriuretic accompanied by an increase in renal protein kinase C (PKC) (; ).
The decrease in NO production is directly related to the state of HT since by losing the ability to produce it; the capacity for vasodilation is also lost in response to increases in blood flow and therefore a continuous increase in pressure of the vessel walls which could lead to the thickening of the vessel walls to be able to withstand this increase in pressure which was reported by Dib et al. and Nehiri et al. who refer to structural changes in the walls of blood vessels and the glomeruli, respectively, which could have implications for pressure values (; ). In the work of Yan et al., they found alterations in the genes of the RAAS, which we know is highly involved in the control of BP, and increased glomerular filtration, which could indicate an early stage of kidney dysfunction (). Table 1 shows a summary of the aforementioned information specifying the rat strains and the dose of STZ used.
TABLE 1
| DAMS | OFFSPRING | Ref. | |||
|---|---|---|---|---|---|
| Animal/Strain | Diabetes model | Glucose levels reached | Age of hypertension start | Proposed mechanism | |
| Rat/Sprague-Dawley | STZ Injection of 35 mg/kg at 0 days of gestation. | 17 mM | 12 weeks | There is fetal vascular programming where AMPK levels are decreased, which could lead to an increase in RE stress, an increase in ROS, and a decrease in NO synthesis | |
| Rat/Wistar | STZ Injection of 25 mg/kg at 0 days of gestation. | 15 mM | 12 weeks | Fetal programming causes an alteration in the expression of the component genes of the RAAS system. An increased glomerular filtration rate was also found, indicating an early stage of renal dysfunction | |
| Rat/Sprague-Dawley | STZ Injection of 35 mg/kg at 0 days of gestation. | 18 mM | 12 weeks | Impaired diuresis and natriuresis are mediated by D1 receptor, accompanied by increased renal PKC expression and activity | |
| Rat/Sprague-Dawley | STZ Injection of 35 mg/kg at 0 days of gestation. | 450 mg/dL (25 mM) | 18 months | Fetal programming led to structural changes in the vasculature: an increase in area of the medial layer and a decrease in arterial diameter, which could be responsible for the increase in BP. | |
| Rat/Sprague-Dawley | STZ Injection of 35 mg/kg at 0 days of gestation. | 20 mM | 6 months | Glomerular hypertrophy, decreased renal function assessed by altered creatinine filtration values and proteinuria | |
Animal models of gestational diabetes using streptozotocin, development of hypertension in offspring and proposed mechanism involved in the development of this cardiovascular disease.
Human studies
Longitudinal studies in humans are difficult to carry out since it is difficult to maintain contact with patients over the years due to changes in residence, loss of contact or simply because they do not want to continue with the study. Despite this, we have found studies of up to 40 years of follow-up in the offspring of mothers with GD and the prevalence of cardiovascular problems.
In a study done by Tsadok et al. where the offspring of GD and non-diabetic mothers in Jerusalem were followed for 17 years, they found a significant difference in weight, BMI, and systolic and diastolic pressure, all of which were higher in the adolescent children of mothers with GD (Gob.mx). In another work carried out by Cho et al. In an American child population (12 and 13 years old), it was found that children descended from mothers with GD presented higher values of BMI, SBP and mean arterial pressure; as well as elevated values at 2 h of both glucose and insulin in the corresponding resistance tolerance curves ().
Yu et al. did a follow-up on the Danish population born between 1977 and 2016 for up to 40 years. They observed a 29% increased risk of developing CVD early in life if they had been exposed to hyperglycemia in the mother’s womb. Different CVD were evaluated, and it was found that these offspring had a 45% higher risk of heart failure, 78% of HT, 82% of deep brain thrombosis and 91% of pulmonary embolism compared to those from mothers with normal blood glucose levels ().
The population of the Viva Project carried out in Massachusetts was followed 3 years after birth to children born to mothers with glucose intolerance developed during pregnancy and GD as such, here they found a significant difference in SBP values, being 1 mmHg and 4 mmHg higher in these groups compared to controls (). This increase in pressure values may seem very small, however, being at a very young age, it is very relevant since in these cases it is observed that the difference concerning the controls becomes larger with time.
Jun Lu et al. did a study in the city of Tianjin, China where they followed the study population for 6 years and found that children who had been exposed to hyperglycemia in the womb and their mothers had a higher body mass index, had higher SBP values and also a higher prevalence of HT, it should be noted that it is a very young age to present this condition (). In addition to HT, other CV conditions have been found in the offspring of mothers with GD, such as arrhythmia at 18 years of age () and heart disease at 1 week of birth ().
Discussion
The prevalence of HT/DM continues to increase throughout the world, so it is of utmost importance to know the binomial present in pregnancy, mechanisms as well as to identify and understand the consequences that these conditions can have on both the mother and the offspring. It has been reported that complications in mothers are normally lost as soon as they give birth; however, the effects on their offspring appear over time.
This review showed a general overview of the coexistence of HT/DM in the general population; but in mothers, GD implies an exposure to hyperglycemia in gestation and increased CV pathologies in the offspring in different stages of their life. In humans, a greater risk of developing HT has been observed from 3 to 40 years of age, where there is already a well-classified development of the disease. In rats, which are the most used animal model for the generation of GD and the evaluation of its effects on the offspring, it has been observed that from 12 weeks they begin to present HT values, structural damage to the blood vessels, and malfunction of the Renal System. This age of 12 weeks in rats extrapolated to humans would represent a child of approximately 8 years (). In most studies, the increase in pressure was observed in SBP, where it has been reported that in adulthood an increase of only 2 mmHg is related to an increase in mortality ().
Different signaling pathways are demonstrated to be involved in this development of HT, such as ER stress, NO synthesis, and generation of ROS, among others (Figure 4). However, it is not known what the timing of these events is, that is, if the disease develops first and then the alterations in these pathways occur or if the disease occurs because these pathways are altered.
FIGURE 4
Another point to consider is the epigenetic changes that occur in the offspring due to exposure to hyperglycemia in the uterus. Epigenetics refers to changes in gene expression without making modifications to the DNA sequence. Within the epigenetic modulators, we can find DNA methylation, histone modification and microRNAs; all of which affect the protein expression levels of the modified genes. In the case of GD, it has been reported that it can affect methylation patterns and gene expression in offspring, which can lead to complications throughout their lives. (). In animal models, it has been found that the epigenetic changes caused by GD can be passed from generation to generation. An example of this is the Dlk1 gene, which is involved in the activation of the insulin/IGF-I signaling pathway and which Jiang et al. found downregulated until the second generation. (). Speaking specifically of CVD, gene modifications have been found in the offspring of mothers with GD at the level of arteries such as the thoracic aorta, where overexpression of potent vasoconstrictors such as Cyp4f4 and downregulation of the IP gene, involved in vasodilation, have been observed. The modifications in the expression of these genes are an example of what could contribute to the development of HT in the offspring of mothers with GD thanks to the prenatal programming given by hyperglycemia in the intrauterine environment. ().
Glucose, being able to cross the placenta by facilitated diffusion, generates problems in both the pregnant mother and the baby when there is a dysregulation in its concentration, so it is important to mention the measures that can be taken to prevent high levels of it. (). In the case of women who are of reproductive age and want to become pregnant, they should try to maintain their normal weight and perform physical activity constantly. (). A woman considered with high risk of GD present these characteristics: severe obesity, a history of GD in first-degree relatives, GD or glucose intolerance in a previous pregnancy, a history of macrosomic products, or current glycosuria. (). In high-risk women, it is recommended to perform glucose screening between 12 and 14 weeks of gestation, in low- and moderate-risk women the screening is performed between 24 and 28 weeks of gestation and is repeated in high-risk women who have had a negative result in the first test. (). Regarding pharmacological treatment for GD, it has been shown that nutritional treatment is sufficient in 80% of patients with GD to reach the therapeutic goal. (). In addition, studies suggest that mild exercise such as a 20- to 45-min walk after eating decreases postprandial blood sugar in women with GD. (). Therefore, pharmacological treatment should only be considered when diet and exercise do not achieve the target figures, in this case, both human rapid-acting insulin and its analogs lispro and aspart are considered safe since their effectiveness has been demonstrated and there are no reports of teratogenicity. (; ).
We highlight the link between the development of alterations in glucose metabolism during pregnancy as a preventable risk factor but that predisposes offspring to suffer CV events during their life.
Being exposed to high glucose concentration in the womb can lead to an increase in ROS and ER stress, a decrease in NO synthesis; thickening of the vessel wall, a decrease in the lumen of the vessel and damages in kidney´s functions and structure that can later on set the development of hypertension. Created by Biorender.
Conclussion
This review confirms the relationship between HT/DM, focusing in hyperglycemia in pregnancy and the risk of CVD in adulthood; however, more studies need to be carried out to be able to define both the causality and the prevalence of the development of HT in the offspring of diabetic mothers, since there are many variations between populations, probably due to lifestyle, genetics, and other factors that remain to be defined.
Limitations of the study
The review was done only with information in free full texts available in PubMed and Web of Science because we didn´t have the means to pay for articles. In the case of animal models, the main limitation of the STZ model is that the mechanism of action of the drug is the destruction of the beta cells of the pancreas and therefore there is no production of insulin, which would resemble type 1 diabetes. However, the progression of GD occurs due to the development of IR (type 2 diabetes). Although it is not the correct way to obtain high blood glucose values in the mothers, what is ultimately important is to expose the offspring to hyperglycemia in their mothers’ wombs and then evaluate its consequences.
Statements
Author contributions
M-HA: Writing–original draft, Writing–review and editing. E-TR: Writing–review and editing. D-LG: Writing–original draft, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT) for the scholarship given to M-HA (865368) and D-LG (775467).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
American Diabetes Association (2007). Nutrition recommendations and interventions for diabetes. A position statement of the American diabetes association. Diabetes Care30 (S1), S48–S65. 10.2337/dc07-S048
2
American diabetes Association (2008). Standards of medical care in diabetes-2008. Diabetes Care31 (S1), S12–S54. 10.2337/dc08-S012
3
AubryE. M.OelhafenS.FankhauserN.RaioL.CignaccoE. L. (2019). Adverse perinatal outcomes for obese women are influenced by the presence of comorbid diabetes and hypertensive disorders. Sci. Rep.9 (1), 9793. 10.1038/s41598-019-46179-8
4
Avgil TsadokM.FriedlanderY.PaltielO.ManorO.MeinerV.HochnerH.et al (2011). Obesity and blood pressure in 17-year-old offspring of mothers with gestational diabetes: insights from the Jerusalem perinatal study. Exp. Diabetes Res.2011, 906154–90615. 10.1155/2011/906154
5
BorghiC.ForceSIIA T.RossiF.ForceS. I. F. T. (2015). Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High. Blood Press Cardiovasc Prev.22, 429–444. 10.1007/s40292-015-0120-5
6
BramhamK.ParnellB.Nelson-PiercyC.SeedP. T.PostonL.ChappellL. C. (2014). Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ348, g2301. 10.1136/bmj.g2301
7
CarrizzoA.IzzoC.OlivetiM.AlfanoA.VirtuosoN.CapunzoM.et al (2018). The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation. Int. J. Mol. Sci.19, 2968. 10.3390/ijms19102968
8
ChengL. S.DavisR. C.RaffelL. J.XiangA. H.WangN.QuinonesM.et al (2001). Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive hispanic families. Circulation104, 1255–1260. 10.1161/hc3601.096729
9
CheungB. M.LiC. (2012). Diabetes and hypertension: is there a common metabolic pathway?Curr. Atheroscler. Rep.14, 160–166. 10.1007/s11883-012-0227-2
10
ChoN. H.SilvermanB. L.RizzoT. A.MetzgerB. E. (2000). Correlations between the intrauterine metabolic environment and blood pressure in adolescent offspring of diabetic mothers. J. Pediatr.136 (5), 587–592. 10.1067/mpd.2000.105129
11
ColosiaA. D.PalenciaR.KhanS. (2013). Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab. Syndr. Obes.6, 327–338. 10.2147/DMSO.S51325
12
ConenD.RidkerP. M.MoraS.BuringJ. E.GlynnR. J. (2007). Blood pressure and risk of developing type 2 diabetes mellitus: the Women’s Health Study. Eur. Heart J.28, 2937–2943. 10.1093/eurheartj/ehm400
13
CunninghamF. G.LevenoK. J.BloomS. L.DasheJ. S.HoffmanB. L.CaseyB. M.et al (2018). Williams obstetrics. Philadelpia, PA: McGraw-Hill Education. 37–7.
14
Diabetes (2019).Who.int. Disponible en. Available online at: https://www.who.int/news-room/fact-sheets/detail/diabetes.
15
Diagnóstico (2009). Guía de Practica Clínica, Diagnóstico y Tratamiento de la Diabetes en el embarazo, México: Secretaría de Salud
16
DibA.PayenC.BourreauJ.MunierM.GrimaudL.FajlounZ.et al (2018). In utero exposure to maternal diabetes is associated with early abnormal vascular structure in offspring. Front. Physiol.9, 350. 10.3389/fphys.2018.00350
17
DłuskiD. F.WolińskaE.SkrzypczakM. (2021). Epigenetic changes in gestational diabetes mellitus. Int. J. Mol. Sci.22 (14), 7649. 10.3390/ijms22147649
18
FerranniniE.BuzzigoliG.BonadonnaR.GioricoM. A.OlegginiM.GraziadeiL.et al (1987). Insulinresistance in essentialhypertension. N. Engl. J. Med.317, 350–357. 10.1056/NEJM198708063170605
19
FoxK.BorerJ. S.CammA. J.DanchinN.FerrariR.Lopez SendonJ. L.et al (2007). Resting heart rate in cardiovascular disease. JACC50, 823–830. 10.1016/j.jacc.2007.04.079
20
FranzagoM.FraticelliF.StuppiaL.VitacolonnaE. (2019). Nutrigenetics, epigenetics and gestational diabetes: consequences in mother and child. Epigenetics14 (3), 215–235. 10.1080/15592294.2019.1582277
21
FukudaN.SatohC.HuW. Y.NakayamaM.KishiokaH.KanmatsuseK. (2001). Endogenous angiotensin ii suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J. Hypertens.19, 1651–1658. 10.1097/00004872-200109000-00018
22
GaedeP.Lund-AndersenH.ParvingH. H.PedersenO. (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med.358 (6), 580–591. 10.1056/NEJMoa0706245
23
Gob.mx (2020). Disponible en: Available online at: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/320GER.pdf.
24
GrunfeldB.BalzaretiM.RomoM.GimenezM.GutmanR. (1994). Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension23, 12–15. 10.1161/01.hyp.23.1_suppl.i12
25
HillisG. S.HataJ.WoodwardM.PerkovicV.ArimaH.ChowC. K.et al (2012). Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. JAHA1, e002832. 10.1161/JAHA.112.002832
26
HuiA. L.LudwigS. M.GardinerP.SevenhuysenG.MurrayR.MorrisM.et al (2006). Community-based exercise and dietary intervention during pregnancy: a pilot study. Can. J. diabetes30 (2), 1–7. 10.1016/s1499-2671(06)02010-7
27
HutcheonJ. A.LisonkovaS.JosephK. S. (2011). Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract. and Res. Clin. obstetrics and Gynaecol.25 (4), 391–403. 10.1016/j.bpobgyn.2011.01.006
28
JiaG.AroorA. R.SowersJ. R. (2017). The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall. Cardiovasc Res.113, 1055–1063. 10.1093/cvr/cvx097
29
JuliusS.KjeldsenS. E.WeberM.BrunnerH. R.EkmanS.HanssonL.et al (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031. 10.1016/S0140-6736(04)16451-9
30
KitzmillerJ.GavinL.GinG.Jovanovic-PetersonL.MainE.ZigrangW. (1991). Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA265, 731–736. 10.1001/jama.1991.03460060063025
31
LangerO. (2006). Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol. Metab. Clin. N. Am.35, 53–78. 10.1016/j.ecl.2005.09.007
32
La Rata de Laboratorio - Relacionar Su Edad Con La de Los Humanos (2022). Scribd. Disponible en. Available online at: https://es.scribd.com/document/498628948/La-rata-de-laboratorio-relacionar-su-edad-con-la-de-los-humanos.
33
LastraG.SyedS.KurukulasuriyaL. R.ManriqueC.SowersJ. R. (2014). Type 2 diabetes mellitus and hypertension: an update. Endocrinol. Metab. Clin. North Am.43, 103–122. 10.1016/j.ecl.2013.09.005
34
LemboG.NapoliR.CapaldoB.RendinaV.IaccarinoG.VolpeM.et al (1992). Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J. Clin. Invest90, 24–29. 10.1172/JCI115842
35
LewandowskaM.WięckowskaB.SajdakS. (2020). Pre-pregnancy obesity, excessive gestational weight gain, and the risk of pregnancy-induced hypertension and gestational diabetes mellitus. J. Clin. Med.9 (6), 1980. 10.3390/jcm9061980
36
Leybovitz-HaleluyaN.WainstockT.LandauD.SheinerE. (2018). Maternal gestational diabetes mellitus and the risk of subsequent pediatric cardiovascular diseases of the offspring: a population-based cohort study with up to 18 years of follow up. Acta Diabetol.55 (10), 1037–1042. 10.1007/s00592-018-1176-1
37
LipS.JeemonP.McCallumL.DominiczakA. F.McInnesG. T.PadmanabhanS. (2016). Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. Eur. Heart J.37, 968–974. 10.1093/eurheartj/ehv557
38
LiuC. Y.ZhangW.JiL. N.WangJ. G.Attendinvestigators. (2019). Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension. Diabetology and Metabolic Syndrome11. 10.1186/s13098-019-0465-3
39
LuJ.ZhangS.LiW.LengJ.WangL.LiuH.et al (2019). Maternal gestational diabetes is associated with offspring’s hypertension. Am. J. Hypertens.32 (4), 335–342. 10.1093/ajh/hpz005
40
LuoH.ChenC.GuoL.XuZ.PengX.WangX.et al (2018). Exposure to maternal diabetes mellitus causes renal dopamine D 1 receptor dysfunction and hypertension in adult rat offspring. Hypertension72 (4), 962–970. 10.1161/hypertensionaha.118.10908
41
LuoH.LanC.FanC.GongX.ChenC.YuC.et al (2022). Down-regulation of AMPK/PPARδ signalling promotes endoplasmic reticulum stress-induced endothelial dysfunction in adult rat offspring exposed to maternal diabetes. Cardiovasc Res.118 (10), 2304–2316. 10.1093/cvr/cvab280
42
MagnussenE. B.VattenL. J.SmithG. D.RomundstadP. R. (2009). Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet. Gynecol.114 (5), 961–970. 10.1097/AOG.0b013e3181bb0dfc
43
ManciaG.GrassiG.ZanchettiA. (2006). New-onset diabetes and antihypertensive drugs. J. Hypertens.24, 3–10. 10.1097/01.hjh.0000194119.42722.21
44
MancusiC.IzzoR.di GioiaG.LosiM. A.BarbatoE.MoriscoC. (2020). Insulin resistance the hinge between hypertension and type 2 diabetes. High blood Press. and Cardiovasc. Prev.27, 515–526. 10.1007/s40292-020-00408-8
45
MarschnerS.PantA.HenryA.Maple‐BrownL. J.MoranL.CheungN. W.et al (2023). Cardiovascular risk management following gestational diabetes and hypertensive disorders of pregnancy: a narrative review. Med. J. Aust.218 (10), 484–491. 10.5694/mja2.51932
46
Martinez-GarciaJ.Vega-MezaJ.Martinez-FelixN.Inzunza-ManjarrezG.Brera-MatienzoJ. Q.MédicoE.et al (2020). Principales malformaciones cardiovasculares en hijos de madres diabeticas Main cardiovascular malformations in children of diabetic mothers. Revmeduas10 (3). 10.28960/revmeduas.2007-8013.v10.n3.003
47
MazzoneG.MoriscoC.LemboV.D’ArgenioG.D’ArmientoM.RossiA.et al (2018). Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats. United Eur. Gastroenterol. J.6, 1056–1064. 10.1177/2050640618774140
48
McIntyreH. D.CatalanoP.ZhangC.DesoyeG.MathiesenE. R.DammP. (2019). Gestational diabetes mellitus. Nat. Rev. Dis. Prim.5, 47. 10.1038/s41572-019-0098-8
49
MeisingerC.DöringA.HeierM. (2008). Blood pressure and risk of type 2 diabetes mellitus in men and women from the general population: the monitoring trends and determinants on cardiovascular diseases/cooperative health research in the region of Augsburg cohort study. J. Hypertens.26, 1809–1815. 10.1097/HJH.0b013e328307c3e9
50
MetzgerB.BuchananT.CoustanD.de LeivaA.DungerD. B.HaddenD. R.et al (2007). Summary and recommendations of the fifth international workshop conference on gestational diabetes mellitus. Diabetes Care30 (S2), S251–S260. 10.2337/dc07-s225
51
MillerJ. A.FlorasJ. S.ZinmanB.SkoreckiK. L.LoganA. G. (1996). Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin. Sci. (Lond).90, 189–195. 10.1042/cs0900189
52
MiyaokaK.KuwasakoT.HiranoK.NozakiS.YamashitaS.MatsuzawaY. (2001). Cd36 deficiency associated with insulin resistance. Lancet.357, 686–687. 10.1016/s0140-6736(00)04138-6
53
MoriscoC.CondorelliG.TrimarcoV.BellisA.MarroneC.CondorelliG.et al (2005). Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ. Res.96, 180–188. 10.1161/01.RES.0000152968.71868.c3
54
National Clinical Guideline Centre (UK) (2020). Hypertension. Royal College of Physicians, 201.
55
NehiriT.Duong Van HuyenJ.-P.ViltardM.FassotC.HeudesD.FreundN.et al (2008). Exposure to maternal diabetes induces salt-sensitive hypertension and impairs renal function in adult rat offspring. Diabetes57 (8), 2167–2175. 10.2337/db07-0780
56
NICE (Clinical) (2015). Guidelines NG136-Hypertension in adults: diagnosis and management, 201.
57
NingZ.SongZ.WangC.PengS.WanX.LiuZ.et al (2021). How perturbated metabolites in diabetes mellitus affect the pathogenesis of hypertension?Front. physiology12, 705588. 10.3389/fphys.2021.705588
58
Org.mx (2013). Disponible en. Available online at: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662017000100091.
59
PetrieJ. R.GuzikT. J.TouyzR. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol.34 (5), 575–584. 10.1016/j.cjca.2017.12.005
60
PhoswaW. N.KhaliqO. P. (2021). The role of oxidative stress in hypertensive disorders of pregnancy (preeclampsia, gestational hypertension) and metabolic disorder of pregnancy (gestational diabetes mellitus). Oxid. Med. Cell Longev.2021, 5581570. 10.1155/2021/5581570
61
PlowsF. J.StanleyL. J.BakerN. P.ReynoldsM. C.VickersH. M. (2018). The pathophysiology of gestational diabetes mellitus. Int. J. Mol. Sci.19, 3342. 10.3390/ijms19113342
62
RanaS.LemoineE.GrangerJ. P.KarumanchiS. A. (2019). Preeclampsia: pathophysiology, challenges, and perspectives. Circ. Res.124, 1094–1112. 10.1161/CIRCRESAHA.118.313276
63
ReddyS.JimB. (2019). Hypertension and pregnancy: management and future risks. Adv. chronic kidney Dis.26 (2), 137–145. 10.1053/j.ackd.2019.03.017
64
ScherrerU.RandinD.VollenweiderP.VollenweiderL.NicodP. (1994). Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. investigation94 (6), 2511–2515. 10.1172/JCI117621
65
SongJ.ShengC. S.HuangQ. F.LiL. H.MaC. S.GuoX. H.et al (2016). Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry. J. Hypertens.34, 1648–1653. 10.1097/HJH.0000000000000994
66
SteinbergH. O.ChakerH.LeamingR.JohnsonA.BrechtelG.BaronA. D. (1996). Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest97, 2601–2610. 10.1172/JCI118709
67
SunD.ZhouT.HeianzaY.LiX.FanM.FonsecaV. A.et al (2019). Type 2 diabetes and hypertension: a study on bidirectional causality. Circulation Res.124 (6), 930–937. 10.1161/CIRCRESAHA.118.314487
68
ThanassoulisG.MassaroJ. M.CorsiniE.RogersI.SchlettC. L.MeigsJ. B.et al (2012). Periaortic adipose tissue and aortic dimensions in the Framingham Heart Study. J. Am. Heart Assoc.1, e000885. 10.1161/JAHA.112.000885
69
Van HuyenJ. D.VessièresE.PerretC.TroiseA.PrinceS.GuihotA.et al (2010). In utero exposure to maternal diabetes impairs vascular expression of prostacyclin receptor in rat offspring. Diabetes59 (10), 2597–2602. 10.2337/db10-0311
70
van OostwaardM. F.LangenveldJ.SchuitE.PapatsonisD. N. M.BrownM. A.ByaruhangaR. N.et al (2015). Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am. J. Obstet. Gynecol.212 (5), 624.e1–624.e17. 10.1016/j.ajog.2015.01.009
71
WangZ.YangT.FuH. (2021). Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: a cross-sectional study. BMC Public Health21 (1), 1224. 10.1186/s12889-021-11122-y
72
WHO (2013). “Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy,” in WHO guidelines approved by the guidelines review committee. Geneva: WHO.
73
World Health Organization (2019). Available online at: https://www.who.int/es/news-room/fact-sheets/detail/hypertension (Accessed August 2024).
74
World Health Organization (2023). Hipertensión. Available online at: https://www.who.int/es/news-room/factsheets/detail/hypertension.
75
World Health Organization (2010). Available online at: https://www.who.int/es/news-room/fact-sheets/detail/diabetes.
76
WrightC. S.Rifas-ShimanS. L.Rich-EdwardsJ. W.TaverasE. M.GillmanM. W.OkenE. (2009). Intrauterine exposure to gestational diabetes, child adiposity, and blood pressure. Am. J. Hypertens.22 (2), 215–220. 10.1038/ajh.2008.326
77
YanJ.LiX.SuR.ZhangK.YangH. (2014). Long-term effects of maternal diabetes on blood pressure and renal function in rat male offspring. PLoS One9 (2), e88269. 10.1371/journal.pone.0088269
78
YangY.WuN. (2022). Gestational diabetes mellitus and preeclampsia: correlation and influencing factors. Front. Cardiovasc. Med.9, 831297. 10.3389/fcvm.2022.831297
79
YaoD.ChangQ.WuQ.-J.GaoS.-Y.ZhaoH.LiuY.-S.et al (2020). Relationship between maternal central obesity and the risk of gestational diabetes mellitus: a systematic review and meta-analysis of cohort studies. J. Diabetes Res.2020, 6303820. 10.1155/2020/6303820
80
YuH. M.LiuG. Z. (2004). Relationship between hypertension, diabetes mellitus, and cardiovascular disease. Mol. Cardiol. China4 (1), 52–55.
81
YuY.ArahO. A.LiewZ.CnattingiusS.OlsenJ.SørensenH. T.et al (2019). Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. BMJ367, l6398. 10.1136/bmj.l6398
82
YusufS.GersteinH.HoogwerfB.PogueJ.BoschJ.WolffenbuttelB. H.et al (2001). Ramipril and the development of diabetes. JAMA286, 1882–1885. 10.1001/jama.286.15.1882
83
ZhengS. L.RoddickA. J.Aghar-JaffarR.Shun-ShinM. J.FrancisD.OliverN.et al (2018). Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA319, 1580–1591. 10.1001/jama.2018.3024
Summary
Keywords
diabetes mellitus, hypertension, insulin resistance, pathophysiological mechanisms, gestational diabetes, hyperglycemia, animal models, humans
Citation
Alejandra M-H, Ricardo E-T and Guadalupe D-L (2025) Crosstalk between hypertension and diabetes: focusing on pregnancy and offspring. A systematic review. Front. Physiol. 16:1519410. doi: 10.3389/fphys.2025.1519410
Received
29 October 2024
Accepted
07 March 2025
Published
25 April 2025
Volume
16 - 2025
Edited by
Keshari Thakali, University of Arkansas for Medical Sciences, United States
Reviewed by
Jan Michael Williams, University of Mississippi Medical Center School of Dentistry, United States
Hina Sultana, University of North Carolina System, United States
Sumaiya Adam, University of Pretoria, South Africa
Updates
Copyright
© 2025 Alejandra, Ricardo and Guadalupe.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Donjuán-Loredo Guadalupe, lupitadon@gmail.com
† These authors share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.